Community pharmacists' experience with pharmacogenetic testing.

Published

Journal Article

Appendix 1 Statements of knowledge of correct medication use Appendix 2 Statements of self-efficacy of correct medication use Appendix 3 Statements of skills of correct medication use To characterize the experiences and feasibility of offering pharmacogenetic (PGx) testing in a community pharmacy setting.Pharmacists were invited to complete a survey about PGx testing for each patient who was offered testing. If the patient consented, pharmacists were also asked to complete a follow-up survey about the process of returning PGx testing results to patients and follow-up with the prescribing provider.Community pharmacies in North Carolina from August through November 2014.Pharmacists at five community pharmacies.Patient consent for testing, time to introduce PGx testing initially and communicate results, interpretation of test results, and recommended medication changes.Of the 69 patients offered testing, 56 (81%) consented. Pre-test counseling typically lasted 1-5 minutes (81%), and most patients (55%) did not have any questions about the testing. Most pharmacists reported test results to patients by phone (84%), with discussions taking less than 1 minute (48%) or 1-5 minutes (52%). Most pharmacists believed the patients understood their results either very well (54%) or somewhat well (41%). Pharmacists correctly interpreted 47 of the 53 test results (89%). All of the incorrect interpretations were for patients with test results indicating a dosing or drug change (6/19; 32%). Pharmacists reported contacting the ordering physician for four patients to discuss results indicating a dosage or drug change.The provision of PGx services in a community pharmacy setting appears feasible, requiring little additional time from the pharmacist, and many patients seem interested in PGx testing. Additional training may be necessary to improve test result interpretation, as well as for communication with both patients and ordering physicians.

Full Text

Duke Authors

Cited Authors

  • Moaddeb, J; Mills, R; Haga, SB

Published Date

  • November 2015

Published In

Volume / Issue

  • 55 / 6

Start / End Page

  • 587 - 594

PubMed ID

  • 26409205

Pubmed Central ID

  • 26409205

Electronic International Standard Serial Number (EISSN)

  • 1544-3450

International Standard Serial Number (ISSN)

  • 1544-3191

Digital Object Identifier (DOI)

  • 10.1331/japha.2015.15017

Language

  • eng